BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 16924086)

  • 1. Preoperative FDG-PET for axillary metastases in patients with breast cancer.
    Chung A; Liou D; Karlan S; Waxman A; Fujimoto K; Hagiike M; Phillips EH
    Arch Surg; 2006 Aug; 141(8):783-8; discussion 788-9. PubMed ID: 16924086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of extra-axillary lymph node involvement with FDG PET/CT in patients with stage II-III breast cancer.
    Aukema TS; Straver ME; Peeters MJ; Russell NS; Gilhuijs KG; Vogel WV; Rutgers EJ; Olmos RA
    Eur J Cancer; 2010 Dec; 46(18):3205-10. PubMed ID: 20719497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer.
    Crippa F; Agresti R; Seregni E; Greco M; Pascali C; Bogni A; Chiesa C; De Sanctis V; Delledonne V; Salvadori B; Leutner M; Bombardieri E
    J Nucl Med; 1998 Jan; 39(1):4-8. PubMed ID: 9443729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual time point 2-deoxy-2-[18F]fluoro-D-glucose PET/CT: nodal staging in locally advanced breast cancer.
    García Vicente AM; Soriano Castrejón A; Cruz Mora MÁ; Ortega Ruiperez C; Espinosa Aunión R; León Martín A; González Ageitos A; Van Gómez López O
    Rev Esp Med Nucl Imagen Mol; 2014; 33(1):1-5. PubMed ID: 23707190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different biological and prognostic breast cancer populations identified by FDG-PET in sentinel node-positive patients: results and clinical implications after eight-years follow-up.
    Agresti R; Crippa F; Sandri M; Martelli G; Tagliabue E; Alessi A; Pellitteri C; Maccauro M; Maugeri I; Barbara P; Rampa M; Moscaroli A; Ferraris C; Carcangiu ML; Bianchi G; Greco M; Bombardieri E
    Breast; 2014 Aug; 23(4):334-40. PubMed ID: 24485802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of macrometastasis in axillary lymph nodes of patients with invasive breast cancer and the utility of the SUV lymph node/tumor ratio using FDG-PET/CT.
    Futamura M; Asano T; Kobayashi K; Morimitsu K; Nawa M; Kanematsu M; Morikawa A; Mori R; Yoshida K
    World J Surg Oncol; 2015 Feb; 13():49. PubMed ID: 25885028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of indication for sentinel lymph node biopsy in clinical node-negative breast cancer using preoperative 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging.
    Taira N; Ohsumi S; Takabatake D; Hara F; Takashima S; Aogi K; Takashima S; Inoue T; Sugata S; Nishimura R
    Jpn J Clin Oncol; 2009 Jan; 39(1):16-21. PubMed ID: 18997183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive Value of
    Song BI; Kim HW; Won KS
    Ann Surg Oncol; 2017 Aug; 24(8):2174-2181. PubMed ID: 28432480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The sensitivity of pre-operative axillary staging in breast cancer: comparison of invasive lobular and ductal carcinoma.
    Topps A; Clay V; Absar M; Howe M; Lim Y; Johnson R; Bundred N
    Eur J Surg Oncol; 2014 Jul; 40(7):813-7. PubMed ID: 24797703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDG-PET for axillary lymph node staging in primary breast cancer.
    Crippa F; Gerali A; Alessi A; Agresti R; Bombardieri E
    Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S97-102. PubMed ID: 15133635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive value of FDG PET/CT for pathologic axillary node involvement after neoadjuvant chemotherapy.
    Keam B; Im SA; Koh Y; Han SW; Oh DY; Cho N; Kim JH; Han W; Kang KW; Moon WK; Kim TY; Park IA; Noh DY; Chung JK; Bang YJ
    Breast Cancer; 2013 Apr; 20(2):167-73. PubMed ID: 22311581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonvisualization of axillary sentinel node during lymphoscintigraphy: is there a pathologic significance in breast cancer?
    Brenot-Rossi I; Houvenaeghel G; Jacquemier J; Bardou VJ; Martino M; Hassan-Sebbag N; Pasquier J
    J Nucl Med; 2003 Aug; 44(8):1232-7. PubMed ID: 12902412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of dual-head coincidence gamma camera FDG imaging with FDG PET in detection of breast cancer and axillary lymph node metastasis.
    Yutani K; Tatsumi M; Shiba E; Kusuoka H; Nishimura T
    J Nucl Med; 1999 Jun; 40(6):1003-8. PubMed ID: 10452318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group.
    Wahl RL; Siegel BA; Coleman RE; Gatsonis CG;
    J Clin Oncol; 2004 Jan; 22(2):277-85. PubMed ID: 14722036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value of PET-FDG in primary breast cancer based on histopathological and immunohistochemical prognostic factors.
    Heudel P; Cimarelli S; Montella A; Bouteille C; Mognetti T
    Int J Clin Oncol; 2010 Dec; 15(6):588-93. PubMed ID: 20809217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of ultrasonography and FDG-PET in axillary lymph node staging of breast cancer.
    Ahn JH; Son EJ; Kim JA; Youk JH; Kim EK; Kwak JY; Ryu YH; Jeong J
    Acta Radiol; 2010 Oct; 51(8):859-65. PubMed ID: 20670083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implication of ¹⁸F-Fluorodeoxyglucose Uptake of Affected Axillary Lymph Nodes in Cases with Breast Cancer.
    Fujii T; Yajima R; Tatsuki H; Oosone K; Kuwano H
    Anticancer Res; 2016 Jan; 36(1):393-7. PubMed ID: 26722071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The value of primary tumor (18)F-FDG uptake on preoperative PET/CT for predicting intratumoral lymphatic invasion and axillary nodal metastasis.
    Jung NY; Kim SH; Kang BJ; Park SY; Chung MH
    Breast Cancer; 2016 Sep; 23(5):712-7. PubMed ID: 26219608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A predictive tool to estimate the risk of axillary metastases in breast cancer patients with negative axillary ultrasound.
    Meretoja TJ; Heikkilä PS; Mansfield AS; Cserni G; Ambrozay E; Boross G; Zgajnar J; Perhavec A; Gazic B; Arisio R; Tvedskov TF; Jensen MB; Leidenius MH
    Ann Surg Oncol; 2014 Jul; 21(7):2229-36. PubMed ID: 24664623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive value of PET-CT for pathological response in stages II and III breast cancer patients following neoadjuvant chemotherapy with docetaxel.
    García García-Esquinas MA; Arrazola García J; García-Sáenz JA; Furió-Bacete V; Fuentes Ferrer ME; Ortega Candil A; Cabrera Martín MN; Carreras Delgado JL
    Rev Esp Med Nucl Imagen Mol; 2014; 33(1):14-21. PubMed ID: 23809513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.